No Data
No Data
Changes in Hong Kong stocks | Cornerstone Pharmaceutical-B (02616) rose more than 26%, leading the innovative drug concept, ASCO catalyzes market conditions, institutions are optimistic about policy+health insurance marginal improvement
Zhitong Finance App learned that innovative drug concept stocks showed strong performance. As of press release, Cornerstone Pharmaceutical-B (02616) rose 26.14% to HK$1.11; Cansino Biotech (06185) rose 16.91% to HK$20.95; Gacos-B (01167) rose 14.2% to HK$1.93; Nuocheng Jianhua (09969) rose 12.31% to HK$5.2; Rongchang Biotech (09995) rose 10.2% to HK$30.8. According to the news, the research title of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was on April 25
The Hang Seng Index rose more than 2%, the Hang Seng Technology Index rose 3.7%, Hong Kong biotech stocks rose higher, Cansino Biotech rose more than 10%, and Rongchang Biotech rose more than 6%.
The Hang Seng Index rose more than 2%, the Hang Seng Technology Index rose 3.7%, Hong Kong biotech stocks rose higher, Cansino Biotech rose more than 10%, and Rongchang Biotech rose more than 6%.
Rongchang Biology (688331): Commercialization promotion, good clinical pipeline progressing in an orderly manner
Revenue of $1,083 billion (+40.26%) was achieved in 2023; net loss to mother was $1,511 million, up slightly year-on-year loss; net loss of $1,543 million was deducted. Revenue growth was mainly due to Tetasepam and Vitacil
Changes in Hong Kong stocks | Rongchang Biotech (09995) fell more than 7%, and the loss in the first quarter increased to 349 million yuan year-on-year, and previously announced a planned increase of 2.55 billion yuan
Rongchang Biotech (09995) fell by more than 7%. As of press release, it was down 7.54% to HK$28.2, with a turnover of HK$483.39 million.
Rongchang Biotech (9995.HK): 1Q24 net loss is in line with expectations; the company maintains 2024 revenue guidance
The 1Q24 net loss was in line with expectations. The company maintains its 2024 revenue guidance. We maintain a “hold” rating and target price of HK$33. In the absence of clear guidelines on the prospects for products to go overseas, we believe that the current stock price is reasonably estimated
Rongchang Biotech (9995.HK): Overseas pipeline promotion and authorization of a new star that is deeply involved in self-avoidance+cancer BIOPHARMA can be anticipated
Taytacip: Using lupus erythematosus as a starting point to create a major FIC free product. Tetacept is the first domestically produced biologic approved to treat systemic lupus erythematosus (SLE). Judging from non-head-to-head comparisons of registered clinical trials, SLE has been approved worldwide
No Data